426 related articles for article (PubMed ID: 24563541)
1. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
3. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Condon SM; Mitsuuchi Y; Deng Y; LaPorte MG; Rippin SR; Haimowitz T; Alexander MD; Kumar PT; Hendi MS; Lee YH; Benetatos CA; Yu G; Kapoor GS; Neiman E; Seipel ME; Burns JM; Graham MA; McKinlay MA; Li X; Wang J; Shi Y; Feltham R; Bettjeman B; Cumming MH; Vince JE; Khan N; Silke J; Day CL; Chunduru SK
J Med Chem; 2014 May; 57(9):3666-77. PubMed ID: 24684347
[TBL] [Abstract][Full Text] [Related]
4. Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
Deng Y; Haimowitz T; LaPorte MG; Rippin SR; Alexander MD; Kumar PT; Hendi MS; Lee YH; Condon SM
ACS Med Chem Lett; 2016 Mar; 7(3):318-23. PubMed ID: 26985322
[TBL] [Abstract][Full Text] [Related]
5. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
[TBL] [Abstract][Full Text] [Related]
7. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
[TBL] [Abstract][Full Text] [Related]
8. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
Knoll G; Ehrenschwender M
FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
11. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
[TBL] [Abstract][Full Text] [Related]
12. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
[TBL] [Abstract][Full Text] [Related]
13. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
14. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
[TBL] [Abstract][Full Text] [Related]
16. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
18. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
[TBL] [Abstract][Full Text] [Related]
19. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
Cossu F; Malvezzi F; Canevari G; Mastrangelo E; Lecis D; Delia D; Seneci P; Scolastico C; Bolognesi M; Milani M
Protein Sci; 2010 Dec; 19(12):2418-29. PubMed ID: 20954235
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
Darding M; Feltham R; Tenev T; Bianchi K; Benetatos C; Silke J; Meier P
Cell Death Differ; 2011 Aug; 18(8):1376-86. PubMed ID: 21331077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
